{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,10,12]],"date-time":"2025-10-12T19:19:54Z","timestamp":1760296794444},"reference-count":47,"publisher":"American Society of Hematology","issue":"8","content-domain":{"domain":["ashpublications.org"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2001,4,15]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:p>Major mechanisms underlying poor immune responses to autologous tumor-associated antigens are overwhelming tumor kinetics and the absence of effective T-cell costimulation by antigen-presenting cells. To address these issues, leukemia and lymphoma mice were treated with the combination of chemotherapy and systemic immunotherapy with recombinant soluble murine B7\u2013immunoglobulin G (IgG) molecules. In this report, 3 murine models were used, a radiation-induced SJL acute myeloid leukemia, a transplantable spontaneous SJL lymphoma, and the C57BL\/6 EL-4 thymic lymphoma. Various treatment modalities were evaluated: single treatments with either B7-IgG or chemotherapy as well as combination therapies. The results demonstrate the following: (1) in all tumor models, the combination of chemotherapy and soluble B7-IgGs is more potent than either therapy alone, leading to cure of tumor-bearing animals; (2) the therapeutic responses are T-cell\u2013dependent, because combined therapy is not efficacious in severe combined immunodeficient mice; (3) the rejection of tumor cells leads to the development of tumor-specific immunity, because cured mice are immune to the rejected tumor but not to a different syngeneic tumor; and (4) 51Cr release assays show that rejection of tumor cells leads to the development of very potent tumor-specific cytotoxic T-lymphocyte activity. On the basis of these results, it is proposed that chemotherapy-mediated tumor reduction, together with consequent augmented tumor-antigen presentation to activated T cells, are primary mechanisms leading to curative responses. The safety profile of the B7-IgG fusion proteins and their synergy with chemotherapy strongly suggest that the combination regimen is a promising strategy in cancer treatment.<\/jats:p>","DOI":"10.1182\/blood.v97.8.2420","type":"journal-article","created":{"date-parts":[[2002,7,27]],"date-time":"2002-07-27T12:46:40Z","timestamp":1027774000000},"page":"2420-2426","update-policy":"http:\/\/dx.doi.org\/10.1182\/blood.2019cm0000","source":"Crossref","is-referenced-by-count":28,"title":["The combination of chemotherapy and systemic immunotherapy with soluble B7\u2013immunoglobulin G leads to cure of murine leukemia and lymphoma and demonstration of tumor-specific memory responses"],"prefix":"10.1182","volume":"97","author":[{"given":"Kathlene","family":"Runyon","sequence":"first","affiliation":[{"name":"From the Genetics Institute, Wyeth-Ayerst Research, Cambridge, MA."}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kwang","family":"Lee","sequence":"additional","affiliation":[{"name":"From the Genetics Institute, Wyeth-Ayerst Research, Cambridge, MA."}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Krystyna","family":"Zuberek","sequence":"additional","affiliation":[{"name":"From the Genetics Institute, Wyeth-Ayerst Research, Cambridge, MA."}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mary","family":"Collins","sequence":"additional","affiliation":[{"name":"From the Genetics Institute, Wyeth-Ayerst Research, Cambridge, MA."}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"John P.","family":"Leonard","sequence":"additional","affiliation":[{"name":"From the Genetics Institute, Wyeth-Ayerst Research, Cambridge, MA."}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kyriaki","family":"Dunussi-Joannopoulos","sequence":"additional","affiliation":[{"name":"From the Genetics Institute, Wyeth-Ayerst Research, Cambridge, MA."}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"234","reference":[{"key":"2020021217270370500_B1","doi-asserted-by":"crossref","first-page":"337","DOI":"10.1146\/annurev.iy.12.040194.002005","article-title":"Tumor-antigens recognized by T lymphocytes.","volume":"12","author":"Boon","year":"1994","journal-title":"Annu Rev Immunol."},{"key":"2020021217270370500_B2","doi-asserted-by":"crossref","first-page":"628","DOI":"10.1016\/S0952-7915(96)80078-1","article-title":"Human tumor antigens recognized by T cells.","volume":"5","author":"Robbins","year":"1996","journal-title":"Curr Opin Immunol."},{"key":"2020021217270370500_B3","doi-asserted-by":"crossref","first-page":"211","DOI":"10.1016\/0167-5699(90)90085-N","article-title":"Role of the CD28 receptor in T-cell activation.","volume":"11","author":"June","year":"1990","journal-title":"Immunol Today."},{"key":"2020021217270370500_B4","doi-asserted-by":"crossref","first-page":"191","DOI":"10.1146\/annurev.iy.11.040193.001203","article-title":"The role of the CD28 receptor during T cell responses to antigen.","volume":"11","author":"Linsley","year":"1993","journal-title":"Annu Rev Immunol."},{"key":"2020021217270370500_B5","doi-asserted-by":"crossref","first-page":"217","DOI":"10.1016\/S0065-2776(08)60431-9","article-title":"Human tumor antigens are ready to fly.","volume":"62","author":"Henderson","year":"1996","journal-title":"Adv Immunol."},{"key":"2020021217270370500_B6","doi-asserted-by":"crossref","first-page":"757","DOI":"10.1016\/S1074-7613(00)80641-X","article-title":"Tumor immunology: the glass is half full.","volume":"9","author":"Sogn","year":"1998","journal-title":"Immunity."},{"key":"2020021217270370500_B7","doi-asserted-by":"crossref","first-page":"525","DOI":"10.1038\/nm0598supp-525","article-title":"Cancer vaccines.","volume":"4","author":"Pardoll","year":"1998","journal-title":"Nat Med."},{"key":"2020021217270370500_B8","doi-asserted-by":"crossref","first-page":"181","DOI":"10.1016\/S0065-2776(08)60911-6","article-title":"Escape of human solid tumors from T-cell recognition: molecular mechanisms and functional significance.","volume":"74","author":"Marincola","year":"2000","journal-title":"Adv Immunol."},{"key":"2020021217270370500_B9","doi-asserted-by":"crossref","first-page":"991","DOI":"10.1146\/annurev.iy.12.040194.005015","article-title":"Tolerance, danger, and the extended family.","volume":"12","author":"Matzinger","year":"1994","journal-title":"Annu Rev Immunol."},{"key":"2020021217270370500_B10","doi-asserted-by":"crossref","first-page":"272","DOI":"10.1093\/jnci\/89.4.272","article-title":"Danger versus tolerance: paradigms for future studies of tumor-specific cytotoxic T lymphocytes.","volume":"89","author":"Fenton","year":"1997","journal-title":"J Natl Cancer Inst."},{"key":"2020021217270370500_B11","doi-asserted-by":"crossref","first-page":"445","DOI":"10.1146\/annurev.iy.07.040189.002305","article-title":"Clonal expansion versus functional clonal inactivation: a costimulatory signalling pathway determines the outcome of T cell antigen receptor occupancy.","volume":"7","author":"Mueller","year":"1989","journal-title":"Annu Rev Immunol."},{"key":"2020021217270370500_B12","doi-asserted-by":"crossref","first-page":"1073","DOI":"10.1016\/0092-8674(89)90044-5","article-title":"Acquisition of immunologic self-tolerance.","volume":"57","author":"Schwartz","year":"1989","journal-title":"Cell."},{"key":"2020021217270370500_B13","doi-asserted-by":"crossref","first-page":"321","DOI":"10.1016\/0167-5699(94)90080-9","article-title":"The B7 and CD28 receptor families.","volume":"15","author":"June","year":"1994","journal-title":"Immunol Today."},{"key":"2020021217270370500_B14","doi-asserted-by":"crossref","first-page":"233","DOI":"10.1146\/annurev.immunol.14.1.233","article-title":"CD28\/B7 system of T cell costimulation.","volume":"14","author":"Lenschow","year":"1996","journal-title":"Annu Rev Immunol."},{"key":"2020021217270370500_B15","doi-asserted-by":"crossref","first-page":"5","DOI":"10.1111\/j.1600-065X.1996.tb00918.x","article-title":"The role of B7\u20131\/B7\u20132:CD28\/CTLA-4 pathways in the prevention of anergy, induction of productive immunity and down-regulation of the immune response.","volume":"153","author":"Boussiotis","year":"1996","journal-title":"Immunol Rev."},{"key":"2020021217270370500_B16","doi-asserted-by":"crossref","first-page":"414","DOI":"10.1016\/0952-7915(94)90120-1","article-title":"CD28\u2013B7 interactions in T-cell activation.","volume":"6","author":"Allison","year":"1994","journal-title":"Curr Opin Immunol."},{"key":"2020021217270370500_B17","doi-asserted-by":"crossref","first-page":"27","DOI":"10.1111\/j.1600-065X.1996.tb00919.x","article-title":"The role of CTLA-4 in the regulation and initiation of T-cell responses.","volume":"153","author":"Chambers","year":"1996","journal-title":"Immunol Rev."},{"key":"2020021217270370500_B18","doi-asserted-by":"crossref","first-page":"985","DOI":"10.1126\/science.270.5238.985","article-title":"Lymphoproliferative disorders with early lethality in mice deficient in CTLA-4.","volume":"270","author":"Waterhouse","year":"1995","journal-title":"Science."},{"key":"2020021217270370500_B19","doi-asserted-by":"crossref","first-page":"483","DOI":"10.1016\/0167-5699(93)90262-J","article-title":"Costimulation of T cells for tumor immunity.","volume":"14","author":"Chen","year":"1993","journal-title":"Immunol Today."},{"key":"2020021217270370500_B20","doi-asserted-by":"crossref","first-page":"682","DOI":"10.1016\/0952-7915(95)80077-8","article-title":"Manipulation of costimulatory signals to enhance antitumor T-cell responses.","volume":"7","author":"Allison","year":"1995","journal-title":"Curr Opin Immunol."},{"key":"2020021217270370500_B21","doi-asserted-by":"crossref","first-page":"1093","DOI":"10.1016\/S0092-8674(05)80059-5","article-title":"Costimulation of antitumor immunity by the B7 counterreceptor for the T lymphocyte molecules CD28 and CTLA-4.","volume":"71","author":"Chen","year":"1992","journal-title":"Cell."},{"key":"2020021217270370500_B22","doi-asserted-by":"crossref","first-page":"368","DOI":"10.1126\/science.7678351","article-title":"Tumor rejection after direct costimualtion of CD8+ T cells by B7-transfected melanoma cells.","volume":"259","author":"Townsend","year":"1993","journal-title":"Science."},{"key":"2020021217270370500_B23","doi-asserted-by":"crossref","first-page":"2507","DOI":"10.1182\/blood.V85.9.2507.bloodjournal8592507","article-title":"Role of B7\u20131 in mediating an immune response to myeloid leukemia cells.","volume":"85","author":"Matulonis","year":"1995","journal-title":"Blood."},{"key":"2020021217270370500_B24","doi-asserted-by":"crossref","first-page":"2938","DOI":"10.1182\/blood.V87.7.2938.bloodjournal8772938","article-title":"Irradiated B7\u20131 transduced primary acute myelogenous leukemia (AML) cells can be used as therapeutic vaccines in murine AML.","volume":"87","author":"Dunussi-Joannopoulos","year":"1996","journal-title":"Blood."},{"key":"2020021217270370500_B25","doi-asserted-by":"crossref","first-page":"417","DOI":"10.1016\/S0065-2776(08)60624-0","article-title":"Gene transfer as cancer therapy.","volume":"58","author":"Dranoff","year":"1995","journal-title":"Adv Immunol."},{"key":"2020021217270370500_B26","doi-asserted-by":"crossref","first-page":"2915","DOI":"10.1182\/blood.V89.8.2915","article-title":"CD8+ T-cells activated during the course of murine acute myelogenous leukemia elicit therapeutic responses to late B7 vaccines after cytoreductive treatment.","volume":"89","author":"Dunussi-Joannopoulos","year":"1997","journal-title":"Blood."},{"key":"2020021217270370500_B27","first-page":"4964","article-title":"Potent activity of soluble B7-IgG fusion proteins in therapy of established tumors and as vaccine adjuvant.","volume":"59","author":"Sturmhoefel","year":"1999","journal-title":"Cancer Res."},{"key":"2020021217270370500_B28","doi-asserted-by":"crossref","first-page":"270","DOI":"10.1016\/S0140-6736(96)08086-5","article-title":"The treatment of acute leukaemia.","volume":"349","author":"Burnett","year":"1997","journal-title":"Lancet."},{"key":"2020021217270370500_B29","doi-asserted-by":"crossref","first-page":"72","DOI":"10.1182\/blood.V95.1.72","article-title":"Effect of time to complete remission on subsequent survival and disease-free survival time in AML, RAEB-t, and RAEB.","volume":"95","author":"Estey","year":"2000","journal-title":"Blood."},{"key":"2020021217270370500_B30","doi-asserted-by":"crossref","first-page":"1249","DOI":"10.1038\/15200","article-title":"Natural adjuvants: endogenous activators of dendritic cells.","volume":"5","author":"Gallucci","year":"1999","journal-title":"Nat Med."},{"key":"2020021217270370500_B31","doi-asserted-by":"crossref","first-page":"423","DOI":"10.1084\/jem.191.3.423","article-title":"Consequences of cell death: exposure to necrotic tumor cells, but not primary tissue cells or apoptotic cells, induces the maturation of immunostimulatory dendritic cells [comment appears in J Exp Med. 2000;191:411-416].","volume":"191","author":"Sauter","year":"2000","journal-title":"J Exp Med."},{"key":"2020021217270370500_B32","doi-asserted-by":"crossref","first-page":"245","DOI":"10.1038\/32588","article-title":"Dendritic cells and the control of immunity.","volume":"392","author":"Banchereau","year":"1998","journal-title":"Nature."},{"key":"2020021217270370500_B33","first-page":"A1004","article-title":"Fc\u03b3R engagement in scid macrophages by soluble B7.2-IgG fusion protein induces upregulation of CD40 and other activation-related molecules [abstract].","volume":"14","author":"Runyon","year":"2000","journal-title":"FASEB J."},{"key":"2020021217270370500_B34","doi-asserted-by":"crossref","first-page":"3795","DOI":"10.4049\/jimmunol.149.12.3795","article-title":"CTLA-4 and CD28 mRNA are coexpressed in most T cells after activation: expression of CTLA-4 and CD28 mRNA does not correlate with the pattern of lymphokine production.","volume":"149","author":"Freeman","year":"1992","journal-title":"J Immunol."},{"key":"2020021217270370500_B35","doi-asserted-by":"crossref","first-page":"3489","DOI":"10.4049\/jimmunol.151.7.3489","article-title":"Characterization of CTLA-4 structure and expression on human T cells.","volume":"151","author":"Lindsten","year":"1993","journal-title":"J Immunol."},{"key":"2020021217270370500_B36","doi-asserted-by":"crossref","first-page":"337","DOI":"10.1038\/358337a0","article-title":"Tyrosine-containing motif that transduces cell activation signals also determines internalization and antigen presentation via type III receptors for IgG.","volume":"358","author":"Amigorena","year":"1992","journal-title":"Nature."},{"key":"2020021217270370500_B37","doi-asserted-by":"crossref","first-page":"2747","DOI":"10.1002\/j.1460-2075.1992.tb05340.x","article-title":"Role of associated gamma-chain in tyrosine kinase activation via murine Fc gamma RIII.","volume":"11","author":"Bonnerot","year":"1992","journal-title":"EMBO J."},{"key":"2020021217270370500_B38","doi-asserted-by":"crossref","first-page":"505","DOI":"10.1084\/jem.187.4.505","article-title":"Type II and III receptors for immunoglobulin G (IgG) control the presentation of different T cell epitopes from single IgG-complexed antigens.","volume":"187","author":"Amigorena","year":"1998","journal-title":"J Exp Med."},{"key":"2020021217270370500_B39","doi-asserted-by":"crossref","first-page":"231","DOI":"10.1007\/s002770050396","article-title":"The IgG Fc receptor family.","volume":"76","author":"Gessner","year":"1998","journal-title":"Ann Hematol."},{"key":"2020021217270370500_B40","first-page":"552","article-title":"Hematopoietic growth factors in the reduction of chemotherapeutic toxicity.","volume":"25","author":"Johnston","year":"1998","journal-title":"Semin Oncol."},{"key":"2020021217270370500_B41","first-page":"361","article-title":"Blood lymphocyte subpopulations in breast cancer patients following post-operative adjuvant chemotherapy or radiotherapy.","volume":"38","author":"Petrini","year":"1979","journal-title":"Clin Exp Immunol."},{"key":"2020021217270370500_B42","doi-asserted-by":"crossref","first-page":"735","DOI":"10.1002\/ijc.2910550506","article-title":"Chemotherapy-induced differential changes in lymphocyte subsets and natural-killer-cell function in patients with advanced breast cancer.","volume":"55","author":"Sewell","year":"1993","journal-title":"Int J Cancer."},{"key":"2020021217270370500_B43","doi-asserted-by":"crossref","first-page":"2221","DOI":"10.1182\/blood.V84.7.2221.2221","article-title":"Lymphocyte depletion during treatment with intensive chemotherapy for cancer.","volume":"84","author":"Mackall","year":"1994","journal-title":"Blood."},{"key":"2020021217270370500_B44","doi-asserted-by":"crossref","first-page":"10","DOI":"10.1634\/stemcells.18-1-10","article-title":"T-cell immunodeficiency following cytotoxic antineoplastic therapy: a review.","volume":"18","author":"Mackall","year":"2000","journal-title":"Stem Cells."},{"key":"2020021217270370500_B45","doi-asserted-by":"crossref","first-page":"221","DOI":"10.1007\/s002620050481","article-title":"Cellular immune responses in acute leukaemia patients with severe chemotherapy-induced leucopenia; characterization of the cytokine repertoire of clonogenic T cells.","volume":"46","author":"Bruserud","year":"1998","journal-title":"Cancer Immunol Immunother."},{"key":"2020021217270370500_B46","doi-asserted-by":"crossref","first-page":"1138","DOI":"10.1054\/bjoc.1999.1053","article-title":"Interferon-gamma in the first-line therapy of ovarian cancer: a randomized phase III trial.","volume":"82","author":"Windbichler","year":"2000","journal-title":"Br J Cancer."},{"key":"2020021217270370500_B47","doi-asserted-by":"crossref","first-page":"517","DOI":"10.1097\/00001622-199811000-00007","article-title":"Recent advances in systemic therapy for breast cancer.","volume":"10","author":"Dees","year":"1998","journal-title":"Curr Opin Oncol."}],"container-title":["Blood"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/ashpublications.org\/blood\/article-pdf\/97\/8\/2420\/1672972\/h8080102420.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"http:\/\/ashpublications.org\/blood\/article-pdf\/97\/8\/2420\/1672972\/h8080102420.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,1,6]],"date-time":"2024-01-06T06:43:05Z","timestamp":1704523385000},"score":1,"resource":{"primary":{"URL":"https:\/\/ashpublications.org\/blood\/article\/97\/8\/2420\/53223\/The-combination-of-chemotherapy-and-systemic"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2001,4,15]]},"references-count":47,"journal-issue":{"issue":"8","published-print":{"date-parts":[[2001,4,15]]}},"URL":"https:\/\/doi.org\/10.1182\/blood.v97.8.2420","relation":{},"ISSN":["1528-0020","0006-4971"],"issn-type":[{"value":"1528-0020","type":"electronic"},{"value":"0006-4971","type":"print"}],"subject":[],"published":{"date-parts":[[2001,4,15]]}}}